Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice

Journal of Controlled Release

Volumn 149, Issue 1, 2011, Pages 8-14

  Nomura, Tetsuya ^a,b   Abe, Yasuhiro ^a   Kamada, Haruhiko ^a,b   Shibata, Hiroko ^a   Kayamuro, Hiroyuki ^a,b   Inoue, Masaki ^a   Kawara, Tomoyuki ^a,b   Arita, Shuhei ^a,b   Furuya, Takeshi ^a,b   Yamashita, Takuya ^a,b   Nagano, Kazuya ^a   Yoshikawa, Tomoaki ^a,b   Yoshioka, Yasuo ^a,b   Mukai, Yohei ^b   Nakagawa, Shinsaku ^b   Taniai, Madoka ^c   Ohta, Tsunetaka ^c   Serada, Satoshi ^a   Naka, Tetsuji ^a   Tsunoda, Shin Ichi ^a,b   Tsutsumi, Yasuo ^a,b   more..

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Experimental autoimmune encephalomyelitis; Multiple sclerosis; PEG R1antTNF; TNFR1 selective antagonist; Tumor necrosis factor

Indexed keywords

EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY CELLS; LYMPH NODE; MULTIPLE SCLEROSIS; PEG-R1ANTTNF; PHAGE DISPLAY TECHNOLOGY; SELECTIVE BLOCKING; SERUM LEVELS; SPINAL CORDS; THERAPEUTIC EFFECTS; THERAPEUTIC POTENTIALS; THERAPEUTIC STRATEGY; TNFR1-SELECTIVE ANTAGONIST; TUMOR NECROSIS FACTORS;

BODY FLUIDS; GLYCOPROTEINS; MACROPHAGES;

TUMORS;

CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 17; INTERLEUKIN 6; PEGYLATED TUMOR NECROSIS FACTOR RECEPTOR TYPE I ANTAGONIST; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DEMYELINATION; DRUG EFFICACY; HISTOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; SPINAL CORD; TH1 CELL; TH17 CELL;

ANIMALS; CELL PROLIFERATION; CYTOKINES; DRUG CARRIERS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; LYMPH NODES; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; MUTATION; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SPINAL CORD; SPLEEN; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651227754     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.12.015     Document Type: Article

References (24)

1. K. Hohnoki, A. Inoue, and C.S. Koh Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage J. Neuroimmunol. 87 1998 27 32
2. Sigrid R. Ruuls, Robert M. Hoek, Vu N. Ngo, Tom McNeil, Linda A. Lucian, Mary J. Janatpour, Heinrich Körner, Heleen Scheerens, Edith M. Hessel, Jason G. Cyster, Leslie M. McEvoy, and Jonathon D. Sedgwick Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation Immunity 15 2001 533 543
3. N. Mohan, E.T. Edwards, T.R. Cupps, P.J. Oliverio, G. Sandberg, H. Crayton, J.R. Richert, and J.N. Siegel Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis Rheum. 44 2001 2862 2869
4. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, Neurology 53 (1999) 457-465.
5. N.L. Sicotte, and R.R. Voskuhl Onset of multiple sclerosis associated with anti-TNF therapy Neurology 57 2001 1885 1888
6. G. Kassiotis, and G. Kollias Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination J. Exp. Med. 193 2001 427 434
7. H.P. Eugster, K. Frei, R. Bachmann, H. Bluethmann, H. Lassmann, and A. Fontana Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1 Eur. J. Immunol. 29 1999 626 632
8. G.C. Suvannavejh, H.O. Lee, J. Padilla, M.C. Dal Canto, T.A. Barrett, and S.D. Miller Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis Cell. Immunol. 205 2000 24 33
9. G. Kollias, and D. Kontoyiannis Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments Cytokine Growth Factor Rev. 13 2002 315 321
10. H. Shibata, Y. Yoshioka, A. Ohkawa, K. Minowa, Y. Mukal, Y. Abe, M. Tanial, T. Nomura, H. Kayamuro, H. Nabeshi, T. Sugita, S. Imal, K. Nagano, T. Yoshikawa, T. Fujita, S. Nakagawa, A. Yamamoto, T. Ohta, T. Hayakawa, T. Mayumi, P. Vandenabeele, B.B. Aggarwal, T. Nakamura, Y. Yamagata, S.-I. Tsunoda, H. Kamada, and Y. Tsutsumi Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist J. Biol. Chem. 283 2008 998 1007
11. H. Shibata, Y. Yoshioka, Y. Abe, A. Ohkawa, T. Nomura, K. Minowa, Y. Mukai, S. Nakagawa, M. Taniai, T. Ohta, H. Kamada, S. Tsunoda, and Y. Tsutsumi The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF Biomaterials 2009
12. K.R. Reddy, T.L. Wright, P.J. Pockros, M. Shiffman, G. Everson, R. Reindollar, M.W. Fried, P.P. Purdum 3rd, D. Jensen, C. Smith, W.M. Lee, T.D. Boyer, A. Lin, S. Pedder, and J. DePamphilis Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C Hepatology 33 2001 433 438
13. M.S. Hershfield PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years Clin. Immunol. Immunopathol. 76 1995 S228 232
14. Y. Yamamoto, Y. Tsutsumi, T. Yoshioka, T. Nishibata, K. Kobayashi, T. Okamoto, Y. Mukai, T. Shimizu, S. Nakagawa, S. Nagata, and Y. Mayumi Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity Nat. Biotechnol. 21 2003 546 552
15. T. Kuwabara, F. Ishikawa, T. Yasuda, K. Aritomi, H. Nakano, Y. Tanaka, Y. Okada, M. Lipp, and T. Kakiuchi CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells J. Immunol. 183 2009 2513 2521
16. S. Serada, M. Fujimoto, M. Mihara, N. Koike, Y. Ohsugi, S. Nomura, H. Yoshida, T. Nishikawa, F. Terabe, T. Ohkawara, T. Takahashi, B. Ripley, A. Kimura, T. Kishimoto, and T. Naka IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis Proc. Natl. Acad. Sci. U. S. A. 105 2008 9041 9046
17. H. Lassmann Mechanisms of demyelination and tissue destruction in multiple sclerosis Clin. Neurol. Neurosurg. 104 2002 168 171
18. L. Steinman Assessment of animal models for MS and demyelinating disease in the design of rational therapy Neuron 24 1999 511 514
19. U. Christen, R. Thuerkauf, R. Stevens, and W. Lesslauer Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities Hum Immunol. 60 1999 774 790
20. M. Sospedra, and R. Martin Immunology of multiple sclerosis Annu. Rev. Immunol. 23 2005 683 747
21. M.A. Gimenez, J.E. Sim, and J.H. Russell TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation J. Neuroimmunol. 151 2004 116 125
22. L. Probert, H.P. Eugster, K. Akassoglou, J. Bauer, K. Frei, H. Lassmann, and A. Fontana TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease Brain 123 Pt 10 2000 2005 2019
23. N. Hövelmeyer, Z. Hao, K. Kranidioti, G. Kassiotis, T. Buch, F. Frommer, L. von Hoch, D. Kramer, L. Minichiello, G. Kollias, H. Lassmann, and A. Waisman Apoptosis of oligodendrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis J. Immunol. 175 2005 5875 5884
24. L. Steinman A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage Nat. Med. 13 2007 139 145